

November 18, 2011

Press Release

Japanese Red Cross Society
[Mitsubishi Tanabe Pharma Corporation](#)

Notice of postponement of integrating the plasma fractionation operations of the Japanese Red Cross Society and Mitsubishi Tanabe Pharma Corporation

The Japanese Red Cross Society (National Headquarters: Minato-ku, Tokyo; President: Tadateru Konoe) and Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; President and CEO: Michihiro Tsuchiya), previously reached a basic agreement to integrate the plasma fractionation operations of the Japanese Red Cross Society and Benesis Corporation, a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation that is engaged in the production and sale of plasma fractionation products, with a target date of April 1, 2012.

Subsequently, earnest discussions were commenced between the two parties, but in consideration of the time required for the establishment of a new corporation and for the obtaining procedures for various business licenses, it was agreed to extend the timing of the operational integration by six months from the initial plans, to October 1, 2012.

Both parties remain committed to the integration of their plasma fractionation operations. Moving forward, they will do their utmost to meet the mandate of the people to provide sustained plasma fractionation operations and efficient, safe plasma fractionation products in Japan.

For further information:

Japanese Red Cross Society

Blood Service Headquarters, Public Relations

TEL: +81-3-3437-7507

Mitsubishi Tanabe Pharma Corporation

Corporate Communications Department

TEL: +81-6-6205-5211